慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响

doi:10.3969/j.issn.1672-5069.2021.03.009

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)患者外周血调节性T淋巴细胞(Treg)/辅助性T细胞17(Th17)平衡及其对替比夫定治疗应答的预测能力。方法 2019年2月～2020年3月我院诊治的123例CHB患者和112例乙型肝炎病毒携带者,另选同期健康人95例,给予CHB患者替比夫定治疗48 w,使用流式细胞仪检测外周血Treg细胞和Th17细胞百分比,计算Treg/Th17比值。采用Logistic多因素回归模型分析影响替比夫定治疗应答的因素,应用受试者工作特征曲线(ROC)下面积(AUC)分析Treg/Th17比值预测替比夫定治疗应答的价值。结果 CHB患者外周血Treg细胞和Th17细胞百分比及Treg/Th17比值分别为(4.8±1.1)%、(6.1±1.7)%和(0.8±0.1),显著高于HBV携带者[分别为(1.1±0.3)%、(2.5±0.8)%和(0.4±0.0),P＜0.05]或健康人[分别为(0.9±0.2)%、(2.1±0.6)%和(0.4±0.0),P＜0.05);在治疗12 w、24 w和48 w, CHB患者血清ALT复常率分别为65.9%、77.2%和93.5%,HBV DNA阴转率分别为61.8%、72.4%和82.9%;在治疗48 w末,21例(17.1%)CHB患者不应答;不应答组复治、服药依从性差、血清ALT水平低、基线HBV DNA载量高、Treg细胞百分比高和Treg/Th17比值高的比率显著高于应答组(P均<0.05);Logistic回归分析显示,复治、基线HBV DNA载量、ALT水平和Treg/Th17比值均为影响替比夫定治疗不应答的独立预测因素(OR=3.695、OR=3.232、OR=3.866、OR=4.039,P均<0.05);ROC分析显示,Treg/Th17比值预测替比夫定治疗不应答的最佳截断点为0.83,AUC为0.923(95%CI:0.860～0.963),其灵敏度为81.0%,特异度为87.3%,准确度为91.1%。结论 CHB患者外周血Treg细胞百分比和Treg/Th17细胞比值异常升高,可能影响替比夫定抗病毒治疗效果,其机制值得进一步研究。

关键词: 慢性乙型肝炎, 替比夫定, 调节性T淋巴细胞, 辅助性T细胞17, 治疗

Abstract: Objective The aim of this study was to investigate the balance of peripheral blood regulatory T lymphocytes (Treg)/helper T cell 17 (Th17) in patients with chronic hepatitis B (CHB) and its impact on response to telbivudine treatment.Methods 123 patients with CHB, 112 hepatitis B viral carriers and 95 healthy persons were recruited in this study in our hospital between February 2019 and March 2020, and all CHB patients received telbivudine treatment for 48 weeks. Peripheral blood Treg and Th17 cell percentages were detected by FCM. The multivariate Logistic regression was applied to analyze the impacting factors of non-response to nucleotide analogue treatment in patients with CHB. The area under the receiver operating characteristic curve (AUROC) was applied to analyze the efficacy of Treg/Th17 ratio in predicting the response to antiviral treatment.Results The percentages of Treg cells and Th17 cells as well as Treg/Th17 ratio in patients with CHB were (4.8±1.1)%, (6.1±1.7)% and (0.8 ± 0.1)], significantly higher than [(1.1±0.3)%, (2.5±0.8)% and (0.4±0.0), P<0.05] in HBV carriers, or [(0.9±0.2)%, (2.1±0.6)% and (0.4±0.0), P<0.05] in healthy persons; at the end of week 12, week 24 and week 48, the normalization rates of serum ALT levels were 65.9%, 77.2% and 93.5%, serum HBV DNA loss were 61.8%, 72.3% and 82.9%; at the end of week 48, 21 patients (17.1%) failed to response to antiviral treatment; the percentages of re-treated patients, poor medication compliance, low baseline serum ALT and HBV DNA loads, Treg cells and Treg/Th17 ratios in non-responders were significantly different as compared to those in response group (all P<0.05); the Logistic regression analysis showed that re-treatment, baseline HBV DNA load and ALT levels, and Treg/Th17 ratio were the independent factors for non-response to nucleotide analog treatment in patients with CHC (OR=3.695, OR=3.232, OR=3.866, OR=4.039, all P<0.05); the ROC analysis showed that the optimal cut-off value of blood Treg/Th17 ratio for predicting non-response to nucleotide analogues treatment in patients with CHB was 0.83, with the AUC of 0.923 (95% CI: 0.860-0.963), ant its sensitivity of 81.0%, the specificity of 87.3%, and the accuracy of 91.1%.Conclusion The percentages of peripheral blood Treg cells increase in patients with CHB, which might impact on the response to antiviral therapy and need further investigation.

Key words: Hepatitis B, Telbivudine, Regulatory T lymphocytes, Helper T cells 17, Therapy

王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.

Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment[J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.

参考文献

[1] El-Maadawy EA, Talaat RM, Ahmed MM, et al. Interleukin-6 promotor gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Hum Immunol, 2019,80(3):208-214.
[2]Kanda T, Goto T, Hirotsu Y, et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis Band C infections: a review. Int J Mol Sci, 2019, 20(6):1358.
[3] Hosseini A, Dolati S, Hashemi V, et al. Regulatory T and T helper 17 cells: Their roles in preeclampsia. J Cell Physiol, 2018, 233(9):6561-6573.
[4] Najafi S, Mirshafiey A. The role of T helper 17 and regulatory T cells in tumor microenvironment. Immunopharmacol, 2019, 41(1):16-24.
[5] Villegas JA, Van Wassenhove J, Le Panse R, et al. An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. Ann N Y Acad Sci, 2018, 1413(1):154-162.
[6] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[7] Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis B virus infection. Gut Liver, 2018, 12(5):497-507.
[8] Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol, 2018, 26(1):33-42.
[9] Khan KN, Yamamoto K, Fujishita A, et al. Differential levels of regulatory T cells and T-helper-17 cells in women with early and advanced endometriosis. J ClinEndocrinol Metab, 2019, 104(10):4715-4729.
[10] Lee GR. The Balance of Th17 versus treg cells in autoimmunity. Int J Mol Sci, 2018, 19(3):730.
[11] Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut, 2018, 67(5):945-952.
[12] Rosenthal P, Ling SC, Belle SH, et al. Combination of entecavir/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection. Hepatology, 2019, 69(6):2326-2337.
[13] Loh SH, Moon HN, Lew BL, et al. Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients. J Eur Acad Dermatol Venereol, 2018, 32(6):1028-1033.
[14] Khurana S, Kumari M, Bhardwaj N, et al. T-helper-17, regulatory T-helper cells related serum markers and IL-13 in the outcome of polytraumatic patients with bacteremia. Iran J Immunol, 2018, 15(4):302-308.
[15] DiToro D, Harbour SN, Bando JK, et al. Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity. Immunity, 2020, 52(4):650-667.
[16] Baban B, Hoda N, Malik A, et al. Impact of cannabidiol treatment on regulatory T-17 cells and neutrophil polarization in acute kidney injury. Am J Physiol Renal Physiol, 2018, 315(4):F1149-F1158.
[17] Shenoy S, Chaurasia S, Edavalath S, et al. Effect of induction therapy on circulating T-helper 17 and T-regulatory cells in active proliferative lupus nephritis. Int J Rheum Dis, 2018, 21(5):1040-1048.
[18] Azizi G, Mirshafiey A, Abolhassani H, et al. Circulating helper T-cell subsets and regulatory T cells in patients with common variable immunodeficiency without known monogenic disease. J Investig Allergol Clin Immunol, 2018, 28(3):172-181.
[19] 邵金曼, 刘妍, 陈容娟, 等. 恩替卡韦耐药的慢性乙型肝炎患者序贯挽救治疗的临床疗效与病毒学演变分析. 解放军医学杂志, 2018, 43(5):367-372.
[20] Cho EJ, Kim SE, Suk KT, et al. Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol, 2017, 23(3):205-211.